Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

3.

Comparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance study.

Schito GC, Marchese A, Elkharrat D, Farrell DJ; PROTEKT Study Group.

J Chemother. 2004 Feb;16(1):13-22.

PMID:
15077994
4.
6.

Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).

Mendes C, Marin ME, Quiñones F, Sifuentes-Osornio J, Siller CC, Castanheira M, Zoccoli CM, López H, Súcari A, Rossi F, Angulo GB, Segura AJ, Starling C, Mimica I, Felmingham D.

Braz J Infect Dis. 2003 Feb;7(1):44-61.

8.
9.

Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.

Jenkins SG, Brown SD, Farrell DJ.

Ann Clin Microbiol Antimicrob. 2008 Jan 11;7:1. doi: 10.1186/1476-0711-7-1.

11.

Comparative activity of telithromycin against typical community-acquired respiratory pathogens.

Buxbaum A, Forsthuber S, Graninger W, Georgopoulos A.

J Antimicrob Chemother. 2003 Sep;52(3):371-4. Epub 2003 Jul 29.

PMID:
12888585
12.
13.
14.

Global surveillance through PROTEKT: the first year.

Grüneberg RN.

J Chemother. 2002 Jul;14 Suppl 3:9-16.

PMID:
12418556
16.
18.
19.

In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae respiratory isolates of children.

Johnson CN, Benjamin WH Jr, Gray BM, Crain MC, Edwards KM, Waites KB.

Int J Antimicrob Agents. 2001 Dec;18(6):531-5.

PMID:
11738340

Supplemental Content

Support Center